279 related articles for article (PubMed ID: 12869391)
21. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
22. Chronic angina: new medical options for treatment.
McCullough PA
Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
[TBL] [Abstract][Full Text] [Related]
23. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
Anderson JR; Nawarskas JJ
Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
[TBL] [Abstract][Full Text] [Related]
24. Metabolic energy metabolism in diabetes: therapeutic implications.
Pogatsa G
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S29-33. PubMed ID: 11286305
[TBL] [Abstract][Full Text] [Related]
25. 4-bromotiglic acid, a novel inhibitor of thiolases and a tool for assessing the cooperation between the membrane-bound and soluble beta-oxidation systems of rat liver mitochondria.
Liang X; Schulz H
Biochemistry; 1998 Nov; 37(44):15548-54. PubMed ID: 9799519
[TBL] [Abstract][Full Text] [Related]
26. [Trimetazidine and cardioprotection during ischemia-reperfusion].
Barsotti A; Di Napoli P
Ital Heart J; 2004 Mar; 5 Suppl 2():29S-36S. PubMed ID: 15074775
[TBL] [Abstract][Full Text] [Related]
27. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H; Zarain-Herzberg A; Maisch B
Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
[TBL] [Abstract][Full Text] [Related]
28. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
Kennedy JA; Horowitz JD
Cardiovasc Drugs Ther; 1998 Sep; 12(4):359-63. PubMed ID: 9825181
[TBL] [Abstract][Full Text] [Related]
29. [Efficiency of trimetazidine treatment of experimental ischemic heart disease in age aspect].
Kukes VG; Zhernakova NI; Gorbach TV; Romashchenko OV; Rumbesht VV
Eksp Klin Farmakol; 2013; 76(2):9-12. PubMed ID: 23631276
[TBL] [Abstract][Full Text] [Related]
30. Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine.
Ovide-Bordeaux S; Bescond-Jacquet A; Grynberg A
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1061-70. PubMed ID: 16445572
[TBL] [Abstract][Full Text] [Related]
31. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia.
Zhang XQ; Yamada S; Barry WH
J Cardiovasc Pharmacol; 2008 May; 51(5):443-9. PubMed ID: 18398379
[TBL] [Abstract][Full Text] [Related]
33. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.
Hwang H; Arcidi JM; Hale SL; Simkhovich BZ; Belardinelli L; Dhalla AK; Shryock JC; Kloner RA
Circulation; 2009 Sep; 120(11 Suppl):S16-21. PubMed ID: 19752362
[TBL] [Abstract][Full Text] [Related]
34. Expression and purification of His-tagged rat mitochondrial 3-ketoacyl-CoA thiolase wild-type and His352 mutant proteins.
Zeng J; Li D
Protein Expr Purif; 2004 Jun; 35(2):320-6. PubMed ID: 15135409
[TBL] [Abstract][Full Text] [Related]
35. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
[TBL] [Abstract][Full Text] [Related]
36. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
Labrid C
Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
[TBL] [Abstract][Full Text] [Related]
37. Effect of L-carnitine on mitochondrial acyl CoA esters in the ischemic dog heart.
Kobayashi A; Fujisawa S
J Mol Cell Cardiol; 1994 Apr; 26(4):499-508. PubMed ID: 8072006
[TBL] [Abstract][Full Text] [Related]
38. Role of metabolically active drugs in the management of ischemic heart disease.
Schofield RS; Hill JA
Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
[TBL] [Abstract][Full Text] [Related]
39. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Lee L; Horowitz J; Frenneaux M
Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
[TBL] [Abstract][Full Text] [Related]
40. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
Stanley WC; Marzilli M
Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
